Patents by Inventor Andre Terzic

Andre Terzic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220339253
    Abstract: This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)) are provided.
    Type: Application
    Filed: July 7, 2022
    Publication date: October 27, 2022
    Inventors: Atta Behfar, Andre Terzic, Ruben Jose Crespo-Diaz
  • Patent number: 11413330
    Abstract: This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk for experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCT) for ST-elevation myocardial infarction (STEMI) are provided.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: August 16, 2022
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Atta Behfar, Andre Terzic, Ruben Jose Crespo-Diaz
  • Publication number: 20220152084
    Abstract: A composition for delivering a biologic to a subject generally includes a particulate substrate and an mRNA encapsulated by the particulate substrate. In some cases, the mRNA bay be indirectly attached to the particulate substrate. The mRNA encodes at least one therapeutic polypeptide. The composition may be delivered to a tissue of a subject to provide a therapeutic benefit to the tissue.
    Type: Application
    Filed: January 3, 2022
    Publication date: May 19, 2022
    Inventors: Atta Behfar, Andre Terzic
  • Publication number: 20210348128
    Abstract: This document relates to methods and materials for making and using cardiopoetic stem cells. For example, methods and materials for delivering one or more nucleic acids (e.g., one or more RNAs) encoding one or more early mesodermal transcription factors to a stem cell to generate a cardiopoetic stem cell are provided.
    Type: Application
    Filed: September 27, 2019
    Publication date: November 11, 2021
    Inventors: Andre Terzic, Atta Behfar
  • Publication number: 20210205229
    Abstract: A platform for introducing a heterologous polynucleotide into a cell so that the cell can express the transcription product of the heterologous polynucleotide includes compositions and methods. The compositions generally include an encapsulating agent and a polynucleotide encapsulated with the encapsulating agent. The encapsulating agent can include a metallic nanoparticle. The polynucleotide includes at least one modification to inhibit degradation of the polynucleotide in cytosol of a cell. In various embodiments, the polynucleotide encodes at least one therapeutic polypeptide or at least one therapeutic RNA. The method includes contacting a composition with a cell and allowing the cell to take up the composition.
    Type: Application
    Filed: May 23, 2019
    Publication date: July 8, 2021
    Inventors: Atta Behfar, Andre Terzic
  • Publication number: 20200353047
    Abstract: This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk for experiencing a major adverse cardiac event as well as methods and materials for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCT) for ST-elevation myocardial infarction (STEMI) are provided.
    Type: Application
    Filed: June 3, 2020
    Publication date: November 12, 2020
    Inventors: Atta Behfar, Andre Terzic, Ruben Jose Crespo-Diaz
  • Publication number: 20200190468
    Abstract: This document provides methods and materials related to generating human cells capable of producing insulin in response to glucose or GLP-1. For example, methods and materials for introducing nucleic acid vectors into human stem cells (e.g., human induced pluripotent stem cells) at particular stages of differentiation to create human cells having the ability to produce and secrete human insulin in response to glucose, GLP-1, or both glucose and GLP-1 as measured by a sensitive perifusion assay are provided.
    Type: Application
    Filed: April 24, 2018
    Publication date: June 18, 2020
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Yasuhiro Ikeda, Yaxi Zhu, Aleksey Matveyenko, Andre Terzic, Yogish C. Kudva, Dennis A. Wigle
  • Patent number: 10682394
    Abstract: This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) are provided.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: June 16, 2020
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Atta Behfar, Andre Terzic, Ruben Jose Crespo-Diaz
  • Patent number: 10596123
    Abstract: A method of delivering exosomes and other micro vesicles to a biological target includes the steps of 1) providing blood, (2) separating plasma from the provided blood, and (3) separating the solution with the exosomes therefrom, (4) encapsulating the exosomes, and (5) delivering the exosomes. The step of encapsulation may be accomplished by water bead process, alginate bead process, spray drying bead formation, or plating. The biological target may be a human or animal heart, bone/joint, wound or skin. A method of encapsulating an exosome, a method of using an encapsulated exosome, compositions including encapsulated exosomes, and an encapsulated exosome per se are also disclosed.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: March 24, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Atta Behfar, Andre Terzic, William Cook, Ruben Crespo
  • Publication number: 20190336264
    Abstract: Embolic protection devices can be used to enhance the treatment of heart conditions such as, but not limited to, heart failure and aortic valve stenosis. For example, this document describes percutaneously-deployable intravascular embolic protection devices and methods for their use. The embolic protection devices can be used to capture and remove embolic materials that could otherwise cause adverse patient effects.
    Type: Application
    Filed: December 1, 2017
    Publication date: November 7, 2019
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Atta Behfar, David L. Joyce, Mandeep Singh, Andre Terzic
  • Publication number: 20190275071
    Abstract: A composition for delivering a biologic to a subject generally includes a particulate substrate and an mRNA encapsulated by the particulate substrate. In some cases, the mRNA bay be indirectly attached to the particulate substrate. The mRNA encodes at least one therapeutic polypeptide. The composition may be delivered to a tissue of a subject to provide a therapeutic benefit to the tissue.
    Type: Application
    Filed: November 22, 2017
    Publication date: September 12, 2019
    Inventors: Atta Behfar, Andre Terzic
  • Publication number: 20180320143
    Abstract: This document provides methods and materials related to induced pluripotent stem cells. For example, induced pluripotent stem cells, compositions containing induced pluripotent stem cells, methods for obtaining induced pluripotent stem cells, and methods for using induced pluripotent stem cells are provided. In addition, methods and materials for using induced pluripotent stem cells to repair tissue (e.g., cardiovascular tissue) in vivo as well as methods and materials for using induced pluripotent stem cells to assess their therapeutic potential in appropriate animal models are provided.
    Type: Application
    Filed: July 2, 2018
    Publication date: November 8, 2018
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Yasuhiro Ikeda, Andre Terzic, Timothy J. Nelson, Amber A. Mael, Almudena J. Martinez Fernandez, Satsuki Yamada
  • Patent number: 10047346
    Abstract: This document provides methods and materials related to induced pluripotent stem cells. For example, induced pluripotent stem cells, compositions containing induced pluripotent stem cells, methods for obtaining induced pluripotent stem cells, and methods for using induced pluripotent stem cells are provided. In addition, methods and materials for using induced pluripotent stem cells to repair tissue (e.g., cardiovascular tissue) in vivo as well as methods and materials for using induced pluripotent stem cells to assess their therapeutic potential in appropriate animal models are provided.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: August 14, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Yasuhiro Ikeda, Andre Terzic, Timothy J. Nelson, Amber A. Mael, Almudena J. Martinez Fernandez, Satsuki Yamada
  • Publication number: 20180214518
    Abstract: This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) are provided.
    Type: Application
    Filed: December 21, 2017
    Publication date: August 2, 2018
    Inventors: Atta Behfar, Andre Terzic, Ruben Jose Crespo-Diaz
  • Publication number: 20180187161
    Abstract: This document provides methods and materials related to differentiating iPS cells into glucose-responsive, insulin-secreting progeny. For example, methods and material for using indolactam V (ILV) and glucagon like peptide-1 (GLP-1) to produce glucose-responsive, insulin-secreting progeny from iPS cells are provided.
    Type: Application
    Filed: February 22, 2018
    Publication date: July 5, 2018
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Tayaramma Thatava, Andre Terzic, Yogish C. Kudva, Yasuhiro Ikeda
  • Publication number: 20180119108
    Abstract: This document provides methods and materials involved obtaining induced pluripotent stem (iPS) cells. For example, methods and materials for increasing the efficiency for making iPS cells as well as methods and materials for selecting iPS cells are provided.
    Type: Application
    Filed: October 16, 2017
    Publication date: May 3, 2018
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Timothy J. Nelson, Andre Terzic, Almudena J. Martinez Fernandez, Clifford D. Folmes
  • Patent number: 9932558
    Abstract: This document relates to compositions containing cardiogenic factors, to methods to obtain cells by culturing initial cells in the presence of such factors; and methods of administering the obtained cells to heart tissue.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: April 3, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Andre Terzic, Atta Behfar
  • Patent number: 9932561
    Abstract: This document provides methods and materials related to differentiating iPS cells into glucose-responsive, insulin-secreting progeny. For example, methods and material for using indolactam V (ILV) and glucagon like peptide-1 (GLP-1) to produce glucose-responsive, insulin-secreting progeny from iPS cells are provided.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: April 3, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Tayaramma Thatava, Andre Terzic, Yogish C. Kudva, Yasuhiro Ikeda
  • Patent number: 9884090
    Abstract: This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)) are provided.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: February 6, 2018
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Atta Behfar, Andre Terzic, Ruben Jose Crespo-Diaz
  • Patent number: 9822343
    Abstract: This document provides methods and materials involved obtaining induced pluripotent stem (iPS) cells. For example, methods and materials for increasing the efficiency for making iPS cells as well as methods and materials for selecting iPS cells are provided.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: November 21, 2017
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Timothy J. Nelson, Andre Terzic, Almudena J. Martinez Fernandez, Clifford D. Folmes